|Table of Contents|

Determination of ginsenoside Rg3 in rat plasma using highperformance liquid chromatographytandem mass spectrometry



Research Field:
Publishing date:



Determination of ginsenoside Rg3 in rat plasma using highperformance liquid chromatographytandem mass spectrometry


XIANG Rongfeng DAI Qing ZHOU Yan YU Mingjie LAI Xiaodan

Department of Pharmacy, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China


ginsenoside Rg3 plasma high-performance liquid chromatography-tandem mass spectrometry pharmacokinetics


ObjectiveTo establish a high-performance liquid chromatographytandem mass spectrometry (HPLCMS/MS) system for determination of ginsenoside Rg3 content in rat plasma. MethodsVenous blood samples were collected from the orbit of 6 rats at different time points after intragastric administration of 20 mg/kg ginsenosides Rg3. Plasma was isolated and the samples were extracted with ethyl acetate, followed by chromatographic separation using a C18 column (2.1 mm×50 mm, 5μm) with acetonitrileammonium acetate (10 mmol/L, containing 0.1% formic acid) (90∶10) as the mobile phase at a flow rate 0.4 mL/min. The detection was accomplished with the electrospray ionization source operated in the negative ionization mode. The pharmacokinetic parameters were computed using DAS 3.3.1 pharmacokinetic software. ResultsThe linear calibration curves of ginsenoside Rg3 in rat plasma were obtained within the concentration range of 2~400 ng/mL. The inter-and intra-batch RSDs and the matrix effect of ginsenoside Rg3 detection were all below 15%. Analysis of the pharmacokinetic parameters showed that in rats, ginsenoside Rg3 had an AUC0-t of 821.659±170.125 ng·h/mL, an AUC0-∞ of 912.468±190.653 ng·h/mL, a Cmax of 138.803±28.997 ng/mL, and a t1/2 of 2.803±0.263 h. ConclusionThis HPLC-MS/MS system allows rapid, sensitive and accurate determination of ginsenoside Rg3 in rat plasma.


[1]黎阳, 张铁军, 刘素香, 陈常青.人参化学成分和药理研究进展[J]. 中草药, 2009, 40(1): 164-166.
LI Y, ZHANG T J, LIU S X, et al. Research progress in  chemical constituents and pharmacological activities of Panax ginseng[J]. Chin Tradit Herb Drugs, 2009, 40(1): 164-166.
[2]王金良, 孔佩艳, 徐葳, 等.人参皂苷Rg3抑制急性白血病骨髓基质细胞HIF1α及VEGF的表达及其机制探讨[J]. 第三军医大学学报, 2010, 32(07): 621-624.
WANG J L, KONG P Y, XU W, et al. Ginsenosisde Rg3 inhibits HIF1α and VEGF expressions in acute leukemia bone marrow stromal cells[J]. J Third Mil Med Univ, 2010, 32(07): 621-624.
[3]何凡, 孙小玲, 宿亚柳, 等. 人参皂苷Rg3及其代谢产物在大鼠体内组织分布研究[J]. 中药药理与临床, 2015, 31(4): 14-16.
HE F, SUN X L, SU Y L, et al. Pharmacokinetics of  ginsenoside Rg3 and its main metabolite in rats determined[J]. ?Pharmacol Clin Chin Materia Medica , 2015, 31(4): 14-16.
[4]江昌, 缪雨青, 周文丽, 等. 人参皂苷Rg3的抗肿瘤作用及研究进展[J]. 临床肿瘤学杂志, 2017, 22(07): 664-667. DOI: 10.3969/j.issn. 10090460.2017.07.019.
JIANG C, MIAO Y Q, ZHOU W L, et al. Research progress of ginsenoside Rg3 in anticancer activities [J]. Chin Clin Oncol, DOI: 10.3969/j.issn.1009 0460.2017.07.019.
[5]MOHANAN P, SUBRAMANIYAM S, MATHIYALAGAN R, et al. The molecular signaling of ginsenosides Rb1, Rg1, Rg3 and their mode of actions[J]. J Ginseng Res, 2017(1-10). DOI: org/10.1016/j.jgr.2017.01.008.
[6]段林瑞, 谢艳华, 王四旺. 人参皂苷Rg3药代动力学及抗肿瘤作用的研究进展[J]. 现代生物医学进展, 2010, 10(4): 770-773.
DUAN L R, XIE Y H, WANG S W. Progress of ginsenoside Rg3 pharmacokinetics and antineoplastic mechanisms[J]. Prog Mod Biomed, 2010, 10(4): 770-773.
[7]刘继华, 卢丹, 刘金平, 等. 大鼠肌内注射20(S)人参皂苷Rg3的药动学研究[J]. 中国药学杂志, 2007, 42(14): 1087-1090. DOI: 10.3321/j.issn: 10012494.2007.14.013.
LIU J H, LU D, LIU J P, et al. Studies on pharmacokinetics of 20(S)Ginsenoside Rg3 after intramuscular administration to rats[J]. Chin Pharm J, 2007, 42(14): 1087-1090. DOI: 10.3321/j.issn: 10012494.2007.14.013.
[8]PENG M, LI X, ZHANG T, et al. Stereoselective pharmacokinetic and metabolism studies of 20(S) and 20(R)ginsenoside Rg epimers in rat plasma by liquid chromatographyelectrospray ionization mass spectrometry[J]. J Pharm Biomed Anal, 2016, 121: 215-224. DOI: 10.1016/j.jpba.2016.01.020.
[9]XIE H T, WANG G J, SUN J G, et al. High performance liquid chromatographicmass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solidphase extraction for pharmacokinetic studies[J]. J Chromatogr B, 2005, 818(2): 167-173. DOI: 10.1016/j.jchromb.2004.12.028.
[10]LI K, CHEN X, XU J, et al. Liquid chromatography/tandem mass spectrometry for pharmacokinetic studies of 20(R)ginsenoside Rg3 in dog[J]. Rapid Commun Mass Spectrom, 2005, 19(6): 813-817. DOI: 10.1002/rcm.1862.
[11]庞焕, 汪海林, 富 力, 等.20(R)人参皂苷Rg3人体药代动力学研究[J]. 药学学报, 2001, 36(3): 170-173. DOI: 10.16438/j.05134870.2001.03.003.
PANG H, WANG H L, FU L, et al. Pharmaco kinetics studies of 20(R) Ginsenoside Rg3 in human volunteers[J]. Acta Pharm Sin, 2001, 36(3): 170173. DOI: 10.16438/j.05134870.2001.03.003.
[12]ZHAO Q, ZHENG X, JIANG J, et al. Determination of ginsenoside Rg3 in human plasma and urine by high performance liquid chromatographytandem mass spectrometry[J]. J Chromatogr B, 2010, 878(24): 22662273. DOI: 10.1016/j.jchromb.2010.06.019.
[13]康安, 钱静, 单进军, 等.人参总皂苷主要成分大鼠体内药动学研究[J]. 中草药, 2015, 46(20): 3045-3050. DOI: 10.7501/j.issn. 02532670.2015. 20.014.
KANG A, QIAN J, SHAN J J, et al. In vivo pharmacokinetic study on total saponins from roots of panax ginseng in rats[J]. Chin Tradit Herb Drugs, 2015, 46(20): 3045-3050. DOI: 10.7501/j.issn. 02532670.2015.20.014.
[14]刘妍如, 史鑫波, 陈永琴, 等.HPLCESIMS/MS法同时测定珠子参中15种皂苷类化合物[J]. 中草药, 2016, 47(19): 3502-3507. DOI: 10.7501/j.issn.02532670. 2016.19.024.
LIU Y R, SHI X B, CHEN Y Q , et al. Simultaneous determination of 15 ginsenosides from panacis majoris rhizoma by HPLCESIMS/MS method[J]. Chin Tradit Herb Drugs, 2016, 47(19): 3502-3507. DOI: 10. 7501/j.issn.02532670.2016.19.024.
[15]国家药典委员会. 中华人民共和国药典[M]. 2015版, 北京: 中国医药科技出版社, 2015: 363-368.
Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China[M]. 2015 Ed, Beijing: Chinese Medicine Science and Technology Press, 2015: 363-368. 


Last Update: 2018-07-03